mRNA–lipid nanoparticle interface (None established; generally referred to as mRNA–LNP interface)

The mRNA–lipid nanoparticle interface is the structured boundary where mRNA molecules interact with lipid nanoparticle components to form a stable, nanoscopic complex capable of protecting mRNA from degradation and facilitating its cellular delivery. LNPs are primarily composed of ionizable cationic lipids, helper lipids (e.g., DOPE, DSPC), cholesterol, and PEG-lipids. The interface's architecture—defined by lipid composition, nanostructure (e.g., lamellar, inverse hexagonal), and charge—determines the encapsulation efficiency, protection of mRNA, endosomal escape potential, and tissue targeting. This supramolecular structure is central to the function of modern mRNA therapeutics, ensuring the mRNA payload reaches the cytosol intact, where it can be translated into protein for therapeutic effect. However, the interface is not a molecular target in the drug-discovery sense; it is a functional feature of drug delivery technology, not a classic biological entity.

Other names

mRNA–LNP interfacemRNA–lipid nanoparticle complexLNP–mRNA interactionmRNA–lipid nanocarrier complex

LNPs protect and transport mRNA into cells, where endosomal escape allows mRNA release into the cytosol for translation into therapeutic protein. The structure and physicochemical properties of the interface directly affect encapsulation, release kinetics, and targeting.